This table contains a 2019 update of all existent MS treatment in the European Union, approved in a centralised procedure by the European Medicines Agency (EMA) or decentralised at national level.

To obtain more treatment-related information click on the names mentioned under ‘Commercial brand’.

The active links send to the EMA website. Once there, click on the EU flag in the top right corner of the screen to select your preferred language.

*Table entries are introduced in a random order

Disease-Modifying Therapies (DMTs)

 

Active

substance


 

 

Commercial brand

 

Pharmaceutical

company

 

Year of

approval

 

Type and frequency of administration



 

 

Glatiramer acetate

 

 

 

Copaxone® 40MG/ML



Copaxone®
20MG/ML

 

 

 

Teva Pharmaceuticals Ltd

 

 

2004 and 2015

 

 

Subcutaneous. Daily or three times per week


Glatiramer acetate
Glatiramer Mylan
20 or 40 mg
(Generic of Copaxone ® )

Mylan

2016 and 2017

Subcutaneous. Daily or three times per week
 

 

Alemtuzumab

 

 

Lemtrada®

 

 

Genzyme

Therapeutics

Ltd

 

 

2013

 

 

Intravenous. Three treatment cycles of five days each per year


Cladribine

Mavenclad®

Merck

2017

Oral. Two courses of treatment throughout 2 years
 

 

Dimethyl fumarate

 

 

Tecfidera®

 

 

Biogen

 

 

2014

 

 

Oral. Twice per day

 

 

Interferon beta-1a

 

 

 

Avonex®

 

 

Biogen

 

 

1997

 

 

Intramuscular. Once per week

 

 

Interferon beta-1a

 

 

Rebif®

 

 

Merck

 

 

1998

 

 

Subcutaneous. Three times per week

 

 

Interferon beta-1b

 

 

 

Betaferon®

 

 

Bayer Pharma

Ag

 

 

1995

 

 

Subcutaneous. Every two days

 

 

Interferon beta-1b

 

 

 

Extavia®

 

 

Novartis

Europharm

Ltd

 

 

2008

 

 

Subcutaneous. Every two days

 

 

Peginterferon beta-1a

 

 

 

Plegridy®

 

 

Biogen

 

 

2014

 

 

Subcutaneous. Every two weeks

 

 

Fingolimod

 

 

 

Gilenya®

 

 

Novartis

Europharm

Ltd

 

 

2011

 

 

Oral. Daily

 

 

Mitoxantrone

(generic since 2006)

 

 

Novantrone®

 

 

Meda Pharma

S.A.U

 

 

 

1998

 

 

Intravenous. Variable frequency. Maximum cumulative dose: 140 mg/ m²

 

 

Natalizumab

 

 

Tysabri®

 

 

Biogen

 

 

2006

 

 

Intravenous. Every four weeks

 

Ocrelizumab Ocrevus® Roche2018Intravenous. Every six months
 

 

Teriflunomide

 

 

Aubagio®

 

 

Sanofi-Aventis

 

 

2013

 

 

Oral. Daily

 

Symptomatic treatments

 

Active

substance


 

 

Commercial brand

 

Pharmaceutical

company

 

Year of

approval

 

Type and frequency of administration



 

 

Cannabidiol / delta-9-tetrahydrocannabinol

 

 

Sativex®

 

 

Almirall, S.A.

 

 

2011

 

 

Oromucosal spray for oral use (4 weeks trial) – individualized number of sprays per day

 


Fampridine

Fampyra®
Biogen
2011
Oral. Twice per day

Table reproduced with the courtesy of our member society Esclerosis Multiple Espana (EME).